Background:
The prespecified FIDELITY analysis of two phase 3 trials found that finerenone reduced the risk of cardiovascular (CV) events in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD); however, the magnitude of benefit in patients without prior CV disease (CVD) has not been characterized. T...
A. Verma, R. Agarwal, S. Anker et al.· Circulation· 0 citations
Older observational studies in cirrhosis and heart failure (HF) suggest that treatment with spironolactone is frequently associated with hyponatraemia, which is mechanistically plausible given the known actions of aldosterone. However, the effect of the nonsteroidal mineralocorticoid receptor antagonist (nsMRA) f...
R. Ono, K. Docherty, A. Henderson et al.· European Heart Journal· 0 citations
Background:
Serum potassium is a known prognostic marker in patients with heart failure (HF) and chronic kidney disease (CKD), with both hypo- and hyperkalemia associated with adverse outcomes. The POTCAST trial demonstrated that targeting a potassium range of 4.5-5.0 mmol/L may be optimal in patients at high risk f...
Henri Lu, B. Claggett, G. Filippatos et al.· Circulation· 0 citations
Patiromer reduced serum potassium across baseline kidney function and hyperkalemia subgroups, with greater effect in patients with reduced kidney function and baseline hyperkalemia, which suggest potential heterogeneity in potassium-lowering effects of patiromer across subgroups.
A. Kalogeropoulos, A. M. Rashid, S. Anker et al.· Kidney360· 0 citations
BACKGROUND
Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces risk of heart and kidney outcomes in people with chronic kidney disease (CKD) and type 2 diabetes (T2D). Heart failure is the leading cause of hospitalization in patients with CKD. Here we evaluated whether the reduction in estimated g...
T. Shafi, S. Anker, B. Pitt et al.· European Journal of Heart Fa...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.